A phase I, open label, maximum tolerated dose-finding study to evaluate the safety and tolerability of 90Y-DOTA-tyr3-octreotide [edotreotide-Y-90] administered by intravenous infusion to children with refractory somatostatin-receptor positive tumours.
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Edotreotide Y-90 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 31 Aug 2018 Biomarkers information updated
- 17 Jun 2016 Status changed from recruiting to completed.
- 25 Mar 2008 New trial record.